Podcasts about Nephrology

Dr. Benjamin HippenMD Fellowship, Heersink School of Medicine, 2004Global Head of Clinical Affairs/CMO for Care Delivery, Fresenius Medical CareMore InformationFresenius Medical Care - Dr. Hippen on the Finalization of the Improving Organ Transplant Access (IOTA) RuleFresenius Medical Care - Dr. Hippen on the Improving Organ Transplant Access RuleFresenius Medical Care - Obesity Trends, Anti-Obesity Drugs, and the Future of CKD Care

In this Nephrology episode, Dr.Samira Farouk discusses the nuances of AKI, why you should be trending Urine like you trend Troponin. Stay tuned to find out the final diagnosis! Session facilitator: Dr.Elena Storz Case Discussants: Dr.Douglas Farrell MD: Nephrology Fellow, Icahn School of Medicine at Mount Sinai Dr. Samira Farouk MD: Associate Professor of Medicine… Read More »Episode 389: Rafael Medina Subspecialty Series – Hypotension and Peaked T waves

Cody Kubiak's story is one of extraordinary resilience, faith, and hope. In this episode, we dive into his powerful journey—from childhood surgeries to receiving a kidney transplant and battling cancer. Through every trial, Cody has shown what it means to persevere and live with purpose. Hear firsthand how he turned hardship into hope, and discover why raising awareness for kidney donation is more important than ever. Dive deeper into Cody's story at kidneysquitwedont.com For more information on Kidney Solutions and to join our supportive community, visit kidneysolutions.org Host: Kent Bressler Producer: Jason Nunez Remember to keep breathing, and don't miss the next amazing episodes of Kent's Kidney Stories!

Les bananes sont une excellente source de nutriments, notamment de potassium, de fibres et de vitamines, mais une consommation excessive peut provoquer divers effets secondaires.1. Déséquilibres nutritionnelsManger trop de bananes peut entraîner un excès de certains nutriments tout en créant des carences. Les bananes sont riches en glucides, notamment en sucres naturels, mais elles manquent de protéines et de lipides. Une alimentation trop riche en bananes au détriment d'autres aliments peut déséquilibrer l'apport en macronutriments et en micronutriments essentiels, conduisant à des déficits en vitamines B12, en fer ou en acides gras essentiels.2. Effets digestifsLes bananes contiennent des fibres solubles qui aident à la digestion, mais en excès, elles peuvent provoquer des ballonnements, des gaz et même de la constipation. Paradoxalement, si elles ne sont pas assez mûres, leur teneur élevée en amidon résistant peut ralentir le transit intestinal. Inversement, des bananes très mûres peuvent avoir un effet laxatif si consommées en grande quantité.3. Hyperkaliémie et risques cardiaquesL'un des principaux risques liés à une surconsommation de bananes est l'excès de potassium, un minéral essentiel au bon fonctionnement du cœur. Une consommation excessive peut entraîner une hyperkaliémie, une condition où les niveaux de potassium dans le sang deviennent trop élevés. Cela peut provoquer des symptômes tels que des palpitations, une faiblesse musculaire, voire, dans les cas extrêmes, des arythmies cardiaques pouvant être dangereuses.Une étude publiée dans le Journal of the American Society of Nephrology (2017) montre que l'hyperkaliémie est particulièrement préoccupante pour les personnes souffrant d'insuffisance rénale. Les reins étant responsables de l'élimination du potassium, leur incapacité à le filtrer efficacement peut rendre la consommation excessive de bananes risquée pour ces individus.4. Excès de sucre et prise de poidsBien que naturelles, les bananes sont riches en glucides, avec environ 14 grammes de sucre par fruit moyen. En consommer trop peut contribuer à une augmentation de la glycémie et, à long terme, favoriser une prise de poids si elles sont consommées en excès sans équilibre avec d'autres nutriments.ConclusionSi les bananes sont un excellent aliment, elles doivent être consommées avec modération. Une alimentation variée et équilibrée reste la clé d'une bonne santé ! Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

March is National Kidney Month. Kidneys are two bean-shaped organs that filter wastes and extra water out of our blood and make urine. Damage to your kidneys means they can't filter blood the way it should, which could lead to kidney disease. Our guest for this episode is Leo Yamaguchi, M.D., associate program director and vice chief of clinical services for the TTUHSC School of Medicine's Internal Medicine Division of Nephrology. Dr. Yamaguchi explains how our kidneys work, some of the causes of kidney disease, how we can keep our kidneys safe and why we might want to consider becoming an organ donor. 

The FiltrateJoel TopfSwapnil HiremathAC GomezSopia AmbrusoNayan AroraSpecial Guests Michelle Rheault, Director, Division of Pediatric Nephrology, Professor of MedicineTiffany Caza, Nephropathologist, Scientist and self-described Freely Filtered fan girlEditing bySimon Topf and Sophia AmbrusoShow Notes10. Healthcare Cyberattacks9. ApoE in C3 glomerulonephropathy8. Workforce woes in Adult and Pediatric Nephrology7. Hyponatremia correction meta-analysis6. Microvascular inflammation increases risk of graft loss - in all of its forms5. Xenotransplantation4. KDIGO CKD Guidelines3. Hypertension control trials (ESPRIT, BPROAD)2. The Renaissance of IgAN: IgAN treatment trials1. FLOW: GLP-1 RAs in CKD

In this special World Kidney Day podcast episode, Martina Pirotta, WKD Campaign Manager on behalf of the ISN, welcomes Dr. José Moura-Neto, President of the Brazilian Society of Nephrology, and Dr. Viviane Calice Silva, Director of the Department of Epidemiology and Prevention of Kidney Diseases at the Brazilian Society of Nephrology to describe the current landscape of chronic kidney disease (CKD) in Brazil. They discuss how Brazil commemorates World Kidney Day, with over 1,000 activities taking place annually, the impact of awareness initiatives, and a significant study on CKD screening using point-of-care creatinine testing across the country.

CME credits: 0.25 Valid until: 04-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/beyond-the-broadcast-expert-insights-on-sglt2-inhibitors-in-cardiometabolic-care/29104/ Are you up to date on the plethora of benefits patients may receive from SGLT2 inhibitors? Learn from a multidisciplinary faculty panel as they use patient case vignettes to review emerging evidence and evolving treatment guidelines related to cardio-renal-metabolic comorbidities such as type 2 diabetes, heart failure, chronic kidney disease, and management of patients post-MI. Tune in for the insights you need to enhance your practice. =

CME credits: 0.25 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/no-patient-left-behind-advancing-ckd-associated-pruritus-care/26637/ Patients with chronic kidney disease-associated pruritus (CKD-aP) often face delays in diagnosis and treatment, as well as potential side effects from some prescribed medicines. Tune in as our experts dive into the burden of CKD-aP symptoms and break down the long-term outcomes and benefits of new and emerging treatments.=

Almost 2400 years ago, Hippocrates said "All disease begins in the gut"; and he was right. With modern scientific methods and studies to prove it, we can see exactly how and why all dieases begin in your gut, and what you can do to stop them. 93% od the leading causes of death are connected to your gut, and this episode is going to explain why that it, how it happens and to give you the tools you need to not only protect yourself and your loved ones, but even to reverse almost any diease.   TOPICS DISCUSSED: Reversing 93% of the leading causes of death The machanisms of how all diease begins in your gut How endotoxins (gut toxins) circulate around your body What they do to your organ systems and your body How to heal and seal your gut Reverse chronic inflammatory diseases How to heal from almost anything   Leave us a Review: https://www.reversablepod.com/review   Need help with your gut? Click the link, or visit gutsolution.ca for help: Get help now   Supplements: Get 15% off Practitioner Grade Supplements (forever) by creating an account   Contact us: reversablepod.com/tips    SOCIAL MEDIA: Instagram  Facebook  YouTube     STUDIES FOR REFERENCE: 1. LPS and Liver Disease: ·       Key Study: Lipopolysaccharides promote hepatic steatosis by activating the TLR4-NF-κB pathway in hepatocytes (Cai et al., 2012, Hepatology). Link: https://pubmed.ncbi.nlm.nih.gov/22025365/ 2. LPS and Kidney Disease: ·       Key Study: Role of lipopolysaccharide in the pathogenesis of kidney injury in sepsis (Matsushita et al., 2021, Nephrology). Link: https://pubmed.ncbi.nlm.nih.gov/33460487/ 3. LPS and Diabetes: ·       Key Study: Gut-derived endotoxin and metabolic inflammation in type 2 diabetes (Cani et al., 2007, Diabetologia). Link: https://pubmed.ncbi.nlm.nih.gov/17471239/ 4. LPS and Cancer: ·       Key Study: Gut microbiota-mediated inflammation in obesity: A link with gastrointestinal cancer (Cani et al., 2018, Nature Reviews Gastroenterology & Hepatology). Link: https://pubmed.ncbi.nlm.nih.gov/29348450/ 5. LPS and Cerebrovascular Disease: ·       Key Study: LPS-induced systemic inflammation exacerbates brain damage in ischemic stroke (Chen et al., 2016, Stroke). Link: https://pubmed.ncbi.nlm.nih.gov/26846899/ 6. LPS and Parkinson's Disease: ·       Key Study: Lipopolysaccharide induces neuroinflammation and dopaminergic neuron loss in Parkinson's disease models (Qin et al., 2007, Journal of Neuroscience). Link: https://pubmed.ncbi.nlm.nih.gov/17360907/ 7. LPS and Hypertension: ·       Key Study: Role of gut-derived endotoxemia in systemic inflammation and hypertension (Tang et al., 2017, Hypertension). Link: https://pubmed.ncbi.nlm.nih.gov/28209750/ 8. LPS and Colon/Gut Diseases: ·       Key Study: Lipopolysaccharides promote intestinal inflammation by disrupting the epithelial barrier (Schmidt et al., 2015, Gut). Link: https://pubmed.ncbi.nlm.nih.gov/25691570/ 9. Studies Supporting LPS's Role in Alzheimer's: ·       Study 1: Microbiome-derived lipopolysaccharide enriched in the perinuclear region of Alzheimer's disease brain (Zhao et al., 2017, Frontiers in Immunology). Link: https://pubmed.ncbi.nlm.nih.gov/28928740/ ·       Study 2: Lipopolysaccharides cause neuronal death and cognitive decline (Molecules, 2022). Link: https://pubmed.ncbi.nlm.nih.gov/35011994/ ·       Study 3: Neuroinflammation and Alzheimer's disease: Mechanisms of action (Nature Neuroscience, 2019). Link: https://pubmed.ncbi.nlm.nih.gov/30842661/

Guest: Donald Kohan, MD, PhD Increased formation of renal endothelin one is associated with renal injury.1 In several studies, activation of the ETA receptor has been shown to contribute to IgA nephropathy (IgAN) progression, and markers of endothelin system activity are elevated in patients with the disease.2,3-5 Join Dr Donald Kohan as he dives into the latest research on this connection, which could provide insight into new tailored therapy approaches for IgAN patients. Dr Kohan is a nephrologist at University of Utah Health in Salt Lake City. References: Kohan DE, Barton M. Kidney Int. 2014;86(5):896-904. doi:10.1038/ki.2014.143 Kohan DE et al. Kid Int Rep. 2023;8(11):2198-2210. doi:10.1016/j.ekir.2023.07.023 Lehrke I et al. J Am Soc Nephrol. 2001;12:2321-2329. doi.org/10.1681/ASN.v12112321 Zanatta CM et al. Ren Fail. 2012;34(3):308-315. doi:10.3109/0886022X.2011.647301 Tycova I et al. Physiol Res. 2018;67:93-105. doi.org/10.33549/physiolres.933670 FA-11319389 12/24

Complement 3 glomerulopathy (C3G) is an ultra-rare kidney disease characterized by overactivation of the alternative complement pathway. This program provides insights into the pathogenesis of the disease. FA-11319389 12/24

High phosphorus (hyperphosphatemia) is a common complication caused by chronic kidney disease. Join us for this NKF Live to learn more about why this happens and how to successfully manage high phosphorus in CKD. During this program, you will hear a kidney doctor, a clinical pharmacist, and a person living with high phosphorus discuss important information to know about when managing high phosphorus.   Dr. Jay Wish is Professor of Clinical Medicine at Indiana University School of Medicine in Indianapolis and Chief Medical Officer for Outpatient Dialysis at Indiana University Health.  He is past president of the National Forum of ESRD Networks, served on the Board of Directors of the Renal Physicians Association and the American Association of Kidney Patients and was the recipient of the latter's Visionary Award in 2005. He has over 150 articles, reviews, and book chapters published, particularly in the areas of ESRD quality oversight/improvement, accountability, anemia management and vascular access. Dr. Katie Cardone is an associate professor at Albany College of Pharmacy and Health Sciences in Albany, NY. She is a clinical pharmacist with a clinical practice and research program focused on improving care in patients with kidney disease in outpatient nephrology and dialysis. She co-led the publication of pharmacy practice standards for pharmacists caring for people with kidney disease. She is a member of the Board of Pharmacy Specialties Ambulatory Care Pharmacy Council and is a fellow of the National Kidney Foundation, the American Society of Nephrology, and the American College of Clinical Pharmacy. Quenton Turner Gee has been on in-center hemodialysis for about 2 years. He was diagnosed with Stage 4 CKD in 2020. After a battle with COVID-19, it quickly progressed to end-stage kidney disease. Since starting on dialysis, he's been advocating for mental health and policies improving access to transplants and kidney innovations.   Additional Resources: Phosphate Lowering Agents High Phosphorus Information NKF Peers   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

2025 will bring BIG changes to the dialysis world.  As of Jan 01, oral phosphorus binders will be part of the dialysis payment bundle, out-of-pocket costs for prescription medications are changing in amounts and payment models, and coverage for certain dental services is expanding, to name a few.  In this episode we will explore how these changes will likely impact patients, nephrologists, and dialysis units. Thanks for joining us on this ride of the Kidney Commute! This episode offers CME/CE credit to eligible listeners. If you'd like to claim credit, please go to kidney.org/podcast-CE to register for this episode and complete requirements. 

Nephrologist Manjula Tamura discusses the downsides of kidney dialysis, especially for old or frail patients. Her field has set its sights on offering alternatives, including supportive medical management without dialysis, dialysis in increments, wearable artificial kidneys, and transplanted kidneys from genetically modified pigs – in addition to advances in preventive care that can help humans avoid kidney failure in the first place. Dialysis can extend life, she says, but it is a lifestyle change. The goal is to ensure that every patient's choice aligns with their values and life goals, Tamura tells host Russ Altman in this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your quest. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Manjula Kurella TamuraConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest, Manjula Tamura, a professor of medicine and nephrology at Stanford University Medical School.(00:02:58) The Kidney's Vital RoleThe kidney's role and why its failure is life-threatening.(00:04:51) Causes of Kidney FailureThe leading causes of kidney failure in developed countries.(00:07:58) Kidney TransplantationThe feasibility, barriers, and supply challenges of kidney transplantation.(00:09:50) The Dialysis ProcessHow hemodialysis and peritoneal dialysis work and patient experiences.(00:14:07) The Evolution of Dialysis TreatmentThe history of dialysis and how Medicare's expansion influenced its use.(00:18:48) Study Design: Emulating Clinical TrialsUsing VA electronic health records to simulate trials on dialysis.(00:25:31) Findings: Survival vs. Time at HomeThe trade-offs between extended survival and reduced time at home.(00:27:02) Quality of Life and DialysisMeasuring quality of life impacts through electronic health records.(00:30:32) The Future of Kidney TreatmentsInnovations like xenotransplantation and wearable artificial kidneys.(00:33:04) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

CME credits: 0.25 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/evaluation-and-management-of-aki-in-cirrhosis-at-the-interface-of-gastroenterology-and-nephrology/26988/ In patients with advanced liver disease, decompensated cirrhosis and portal hypertension can impact kidney function through development of acute kidney injury (AKI). Multiple different etiologies of AKI can be seen in cirrhotic patients, including prerenal AKI, acute tubular injury, and hepatorenal syndrome (HRS), which require different treatment approaches. This podcast will emphasize the importance of multidisciplinary care and use of established protocols in treating these patients, particularly when considering a bridge to liver transplantation, and discuss specific considerations for patients with transjugular intrahepatic portosystemic shunt (TIPS).=

CME credits: 0.25 Valid until: 15-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/breaking-the-cycle-addressing-hyperkalemia-in-ckd-and-heart-failure-to-optimize-raasi-therapy/26746/ Patients with CKD or heart failure face the risk of developing hyperkalemia, and healthcare providers often experience clinical inertia in their treatment. Join the experts as they explore chronic hyperkalemia management, and the role of potassium binders. =

In this episode, Alex Liang, CEO of Dallas Nephrology Associates, discusses the challenges and opportunities in nephrology, including the transition to value-based care, the impact of Medicare Advantage, and the importance of maintaining independent practices. He shares leadership insights and strategies for adapting to the rapidly evolving healthcare landscape while prioritizing patient care and organizational integrity.

CME credits: 1.25 Valid until: 10-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/ns-mras-and-biomarkers-the-nt-probnp-connection/30064/ Discover the transformative potential of nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs) in optimizing care for patients with the Cardiovascular-Kidney-Metabolic syndrome. Emerging data presented at EASD, HFSA, ASN and AHA, highlight their ability to improve cardiorenal outcomes in the spectrum of the Cardiovascular-Kidney-Metabolic syndrome. By integrating ns-MRAs into individualized treatment plans, healthcare professionals can offer their patients advanced care backed by cutting-edge research.

CME credits: 1.25 Valid until: 10-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/elevating-hf-care-with-ns-mras-the-future-is-now/30065/ Discover the transformative potential of nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs) in optimizing care for patients with the Cardiovascular-Kidney-Metabolic syndrome. Emerging data presented at EASD, HFSA, ASN and AHA, highlight their ability to improve cardiorenal outcomes in the spectrum of the Cardiovascular-Kidney-Metabolic syndrome. By integrating ns-MRAs into individualized treatment plans, healthcare professionals can offer their patients advanced care backed by cutting-edge research.

Up next for our curriculum series is an episode on Nephrology! Take a listen so that you're prepared for our pre-test! Authors: Dr. Lara Melo Soares Pinho de Carvalho, PGY-3, and Dr. Ritika Kompella, Chief Medical Resident, UCONN  Host: Dr. Ritika Kompella, Chief Medical Resident, UCONN  Guest speakers:  Acute kidney injury in liver failure: Dr. Ruchir Trivedi, Associate Professor of Medicine, Department of Nephrology Paraproteinemia and Amyloidosis- Dr. Srimathi Manickaratnam, Department of Nephrology  Hyponatremia: Dr. Lalarukh Haider, Department of Nephrology

CME credits: 0.25 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/unmasking-igan-from-suspicion-to-timely-diagnosis/26629/ Because renal biopsy is required for diagnosis, providers must be able to identify the histopathological characteristics of IgA nephropathy and implement a systemic diagnostic approach. In addition, the mechanisms of action of some IgAN therapies may offer advantages over others in targeting specific pathways in disease pathophysiology. Join the experts for an exploration of these important clinical topics using a patient case study.=

Chronic kidney disease develops among 30% to 40% of people with type 1 or type 2 diabetes during their lifetime. Author Ian H. de Boer, MD, MS, of the University of Washington Division of Nephrology, discusses the evaluation and treatment of chronic kidney disease in patients with type 1 and type 2 diabetes with JAMA Senior Editor Karen Lasser, MD, MPH. Related Content: Diabetes and Chronic Kidney Disease

Cannabis or marijuana is becoming increasingly more popular in the United States for recreational and medical use. What is cannabis? Are there benefits to using it? Is it ok for someone with kidney disease or dialysis to use it? Learn all this and more in today's episode. Joshua Rein, DO, FASN, is a board-certified nephrologist, kidney physiologist, and certified hypertension specialist. He is an Assistant Professor in the Barbara T. Murphy Division of Nephrology in the Department of Medicine at the Icahn School of Medicine at Mount Sinai in NYC and a Staff Physician at the James J. Peters, Veterans Affairs Medical Center. He received his medical degree from the New York College of Osteopathic Medicine, completed internal medicine at Mount Sinai Beth Israel, and completed clinical and research nephrology fellowships at Mount Sinai Hospital. Dr. Rein is interested in the effects of cannabis and cannabinoids on kidney health and disease given their widespread growing popularity despite an uncertain impact on health. Dr. Rein's research, funded by a Veterans Affairs Career Development Award, utilizes preclinical animal models to characterize the kidney endocannabinoid system and examine the physiological impact of cannabinoids on the regulation of fluid and electrolyte balance by the kidney. His clinical research focuses on the risks, benefits, and clinical significance of cannabis consumption among people with kidney disease and those at risk for developing kidney disease.   Additional Resources: Nephrologist's Guide to Cannabis Cannabis Usage Study AJKD Blog   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

Dr. Jeremy Pepin of Advanced Kidney Care explores the growing role of ASCs in interventional nephrology. He discusses key trends, operational benefits for dialysis patients, and the future of this evolving care setting. This episode is sponsored by Surgery Partners.

CME credits: 0.25 Valid until: 16-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/finally-i-can-take-a-break-from-my-itch-optimizing-ckd-ap-treatment/26639/ Patients with advanced kidney disease undergoing dialysis are frequently affected by the symptom clusters of chronic kidney disease-associated pruritus, or CKD-aP. These symptoms have the potential to significantly diminish patients' quality of life by affecting sleep, mental health, and more. This activity reviews best practices for communicating with patients about symptoms and how to use shared decision-making strategies to develop personalized CKD-aP treatment plans.=

CME credits: 0.25 Valid until: 13-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-igan-care-from-kidney-week/26628/ In this review of clinical trial results, experts cover the latest data in IgA nephropathy and discuss how their application can improve outcomes for your patients. Studies presented include SPARTAN, SPARTACUS, and the PROTECT open-label extension. Throughout this conversation, faculty also consider the anticipated updates to the KDIGO clinical guidelines. =

In this episode, we explore the importance of patient involvement in shaping rare condition research initiatives. Our guests discuss why it's crucial to involve individuals with lived experiences, including patients and caregivers, in setting research agendas. In doing so, this approach ensures research can be more inclusive, efficient, and impactful, addressing the issues that matter most to those affected. Mel Dixon, Founder Cure DHDDS and member of Genomics England Participant Panel is joined by Jo Balfour, Founder of CamRARE and Dr Rona Smith, Senior Research Associate at the University of Cambridge and Honorary Consultant in Nephrology and Vasculitis. Find out more about the Cambridge Rare Disease Research Network, discussed in the episode, which aims to support the rare condition community in building an online network of partnerships and resources to facilitate new patient-centred research opportunities. "We're really turning research on its head, moving away from it being a researcher-led activity where they decide on the idea and the research concept and bring patients in at different points along that research journey and instead starting with the patient's idea in the first place.  It can only be a better system for all because it improves efficiency, it improves potentially the long term outputs and, most importantly, outcomes for patients." You can download the transcript or read it below. Mel: Welcome to Behind the Genes. Rona: I think it really means that we measure what matters to patients and individuals that are affected.  Often, it's really difficult to capture kind of the real impact of disease and there's a tendency for researchers to measure things that are easy to measure and are reproducible, which of course is important but what's most important is actually being able to truly capture the impact of an intervention on an individual's condition.  So, I think that's another key aspect of having people with lived experience involved right from the start. Mel: My name is Mel Dixon and I'm a member of the Participant Panel at Genomics England and founder of Cure DHDDS, a charity set up to raise awareness, support families and help drive research into the ultra-rare DHDDS gene variant.  On today's episode I'm joined by Jo Balfour, Managing Director of CamRARE, which is the Cambridge Rare Disease Network.  This network unites patients, advocates, experts and leaders to address the challenges faced by people affected by rare conditions.  I'm also joined by Rona Smith, Associate Professor at the University of Cambridge and honorary consultant in nephrology and vasculitis.  Today we'll be discussing the role of patients in setting research agendas and how their involvement can lead to more impactful and patient-centred research.  If you enjoy today's episode we'd love your support.  Please like, share and rate us on wherever you listen to your podcasts. Before we begin the interview I'd like to share a little bit of my story.  In November 2022, following whole genome sequencing, we received the news that two of our three children carried a neurodevelopmental and neurodegenerative DHDDS genetic variant.  At the time of our children's diagnosis there was very little information on our gene, minimal research happening into it and no treatment pathway.  Through our charity, Cure DHDDS, we have worked tirelessly to instigate research and create a collaborative scientific research community.  I am a huge advocate for patient-led research and have witnessed first-hand the positive impact it can have on patient lives.  Thanks to the work of the many scientists that we have had the honour of collaborating with, within two years of our children's diagnosis we have a disease-modifying therapy in our sight and an ASO (Antisense oligonucleotides) therapy in development.  We are incredibly grateful for the opportunities genetic testing has given us but I also appreciate how overwhelming a genetic diagnosis can be and how challenging it can be for families to initiate research projects with little to no resources, and that's why initiatives such as CamRARE that we'll be discussing today are so important.   On that note, let's get back to our podcast guests.  I wonder before we dive into today's topic if you could both give a brief introduction, and, Rona, if you could also give the less scientifically-minded of us an explanation about what nephrology is. Rona: Thank you for inviting me today.  So I'm Rona Smith, I work in Cambridge and I'm a nephrologist and that means somebody that looks after individuals who have diseases that affect their kidneys.  My specialist interest is in something called vasculitis which is a rare autoimmune disease that affects all organs in the body but kidneys as well.  Mel: Thank you.  And Jo?  Jo: Hi Mel.  I'm Jo Balfour, the Managing Director and one of the founding members of Cambridge Rare Disease Network, or CamRARE for short.  I think we're often described as the ‘Chief Everything Officers'.  I manage the charity and all of our operations and our wonderful team.    Mel: Lovely.  Thank you very much.  Rona, I wonder also if you could explain to our listeners what is a research agenda?  Rona: So in brief a research agenda is really a strategy that outlines key questions or topics that a research community, and that might be investigators, clinicians, scientists, patients, industry,  and they are the priorities that they want to explore and address over a period of time.  So it's really a direction of travel and identification of areas of importance and where there are gaps in knowledge so that it then leads to the opportunity to form specific research questions that you can then go on and address.  Mel: Why do you both think it's important to involve patients in setting these research agendas?  Jo: Well I think critically one of the things that I've learnt over my time working, not just in the rare disease sector but also earlier in social care and education, is that we should as professionals never assume anything; you know, we have not lived in their shoes and we don't know what the daily life of people living with rare conditions is like.  So gathering that day to day lived experience is really crucial.  And I have a unique opportunity to see into that daily life with our local community of rare disease families who have a range of different rare conditions.  I'm party to their conversations, to their daily trials and tribulations, the things that are difficult, the things that they find joy in but I still will always go back to them and ask their opinion.  I see myself as a spokesperson for them as we're an umbrella organisation but I certainly never really know what it's like to live with their conditions.  I think they bring with them diverse experiences which we really need and value in setting research priorities, they have unique knowledge of their own conditions.  They ethically have a right to be involved from the start and to set that priority and agenda but, equally, it's valuable for us as researchers because if we can involve people early we have definitely more chance of good engagement and later success, better outcomes for everyone.  Mel: Couldn't agree more.  And, Rona, is there anything you'd like to add to that? Rona: I think it really means that we measure what matters to patients and individuals that are affected.  Often it's really difficult to capture kind of the real impact of disease and there's a tendency for researchers to measure things that are easy to measure and are reproducible, which of course is important but what's most important is actually being able to truly capture the impact of an intervention on an individual's condition.  So I think that's another key aspect of having people with lived experience involved right from the start.  Jo: Another thing that's actually quite interesting that I'm going to mention here is that I think when you live day in, day out with a condition your perception of things like pain is different from your average person's so you become almost accepting of your daily norm, and I think that's really critical to understand as well.  And it's only by getting to really know patients and understand. When we say, “What's your pain like on a scale of 1 to 10?” you know, something that I feel as pain because I get it rarely I probably am going to put it at a higher score than somebody who has that every day.  So I think there's subtleties and nuances like that as well which are really critical to get across by conversation with patients.  Mel: That makes absolute sense.  And I see that from the patient perspective myself.  I was out with my friends the other day and they said, “Oh my goodness, you're constantly taking your children to sports activities.”  Because of their physical needs we're constantly,  they go to Pilates, they go to swimming, they go to gym class – we try to keep them fit and healthy – and we, even though they're older, have to take them there and back and that's become our norm but when you're speaking to families whose children don't have those difficulties they have no idea how much time that actually takes up.  And I had no idea how much like time it takes up compared to what other people are doing because that is our norm, that's what we've accepted as the norm.  Patients and patient groups are incredibly driven and invested in their rare disease as well so they make really good rare disease research partners.     And, moving on, what do you see as the challenges and barriers to patient involvement and how do we overcome these? Rona: I think probably the biggest barrier is time.  So, the most important thing is investing time to build relationships, to really understand in-depth perspectives both from the patient's side but also the researcher's side. And, inevitably, we always want to do things faster and actually this is one really, really critical aspect is investing time.  Funding is also a challenge.  Often you have to do a lot of upstream work before you have got funding for a project and that takes time from individuals and that's another challenge.  And I think the third thing for me is individuals that are patient partners in research, they're not just patients, they're people - they have lives, they have work, they have families, they have everything else that goes on in life - and so actually fitting this all in is really challenging.  Mel: Jo, is there anything you'd like to add there?  Jo: Yeah, I think just a word about diversity really and, you know, how do we uncover those hidden families and patients who currently don't really have a voice.  I think we'd all acknowledge that there are key voices within the rare disease community who will share the views of their community and they've become well-oiled machines almost at being great advocates but, as I mentioned earlier, even though I'm perhaps one of those people, you know, I speak for a community, I would never assume anything.  So, I still need to uncover the thoughts and the feelings and the emotions and the needs and the what matters from those people, and, as Rona mentioned, that takes time and it takes building relationships and trust with people.  So, we have a wonderful community in the Eastern region of England which is made up of families affected by all different rare diseases, and undiagnosed.  And some are babies and have been lucky enough to get a very early diagnosis and others are young adults but what we're finding through that is that experience is diverse and experience changes over time as families go through transition periods or they meet a roadblock and they're having to navigate things differently.  So, it's about building those relationships.  That takes times, it takes resources, it takes sometimes a reset in the way that we think things need to be done.  So instead of asking questions all the time and putting surveys out and trying to get response that way it takes a bit of thinking about how do we listen better and how do we give those people who don't have a voice, who are non-verbal or perhaps have a learning disability, how do we ensure that we're capturing their views as well.    And we did a really lovely project actually last year, it was something funded by the NHS called My Story, My Way, where we actually spent three months with our young adults working out what it was they wanted from our community next, how did they want us to follow them into adulthood.  And we knew that there were a number of young people in that group who were non-verbal and had some learning differences and we knew that we couldn't just do it in the normal format, we couldn't just do a focus group and ask their opinion, so we actually did it through photography.  So each of the familiess well, the young person themself was given a simple camera.  They basically had thirty-six shots.  You got thirty-six clicks to capture the things, the people, the places that you love and then to share them with us as a community.  And then we all discuss, you know, how these things might be something we can build into our future plans for them.  And it was such a wonderful activity.  We gave them plenty of time, plenty of opportunities to ask questions.  If the young person themself couldn't physically click the camera their sibling got to help them.  And their sibling or their parent was given another camera in black and white so we had distinctive pictures, pictures that the kid themself had taken, pictures that the family had taken, but all together, you know, it gave this lovely kind of medley, this beautiful visual representations of what mattered to them.  And I think it's about taking the time to be creative with people like that and really get to the bottom of “How do we find out what matters to you?” Mel: Although it takes time to think about those ideas.  That could be translatable across the board really, couldn't it, throughout various conditions.  I think that's fantastic.  Rona, I wonder if you can tell us how has the work that's already been done through the patient-led research hub facilitated addressing research priorities.  Rona: So just a tiny bit about the patient-led research hub.  So, this has been now running for nearly ten years through Cambridge.  It's a partnership between the Cambridge Biomedical Research Campus and we're based within the university and the Trust.  And in essence it kind of was set up because of really a mismatch between what many patients wanted from research and what investigators' views were.  And so really the premise is that we welcome patients to come to us with an idea, a problem, an unmet need in their disease area – and we do focus on rare disease – and we work with them to see “Well actually what do we already know about that?” and then if there is a gap in knowledge we then move to kind of trying to work and develop a question that we can then address.  And that might be a question that's addressed through generating more information through surveys or it may actually be a question of an intervention that we can test.  So, we've had lots of projects come through and we, just an example of a project was from a group of patients with a rare kidney condition called autosomal dominant polycystic kidney disease, and that is a condition where over time you accumulate cysts in your kidneys and the kidneys become large, they become very painful and eventually they can fail.  And a question that the patient group had was about whether drinking more water could impact the rate of growth of these cysts, and there's a strong hypothesis behind that that drinking lots of water reduces down the level of a particular hormone.  And we actually worked with the charity behind this group, the Polycystic Kidney Disease Charity, and designed a study to test a very high water intake to a normal water intake to see whether it was possible over a period of eight weeks for patients to actually stick to this.  It's quite difficult to do.  And they recorded how much water they'd drunk, they tested their own urine and actually it showed that this was feasible to do this kind of work.  So, I think the patient-led research hub is kind of taking the research priorities that are important to patients but working in a patient-led way to come right through to a project.  Mel: That sounds great.  And if the patients are engaged from the start of the project and it's led by them they're obviously going to be much more driven to take part in the actual research and see the research through themselves.    So, Jo, I'm very excited to hear about the launch of the Rare Disease Research Network.  Can you please tell me what the research network is and what you hope to achieve with it?  Jo: So the Rare Disease Research Network is first of all a bit of a mouthful so we're going to try and encourage people to call it the RDRN.  It's a co-created project which really the patient-led research hub in Cambridge approached us about in 2022, I think, we started talking about this, approached CamRARE as a partner to apply for an NIHR partnership grant, and we were successful with that to really take the model that the patient-led research hub had already developed and found was successful, and perhaps too successful for its own good – they were receiving more applications and more ideas than they could manage – and to develop that into an online platform.  So taking the same model, making it more accessible to a wider group of people, potentially worldwide, and providing the hand-holding that the patient-led research hub has always done, helping patients really consider their question, formulate that into a research idea, then do the literature search to find out “Is this question already answered, and if it is, great, can we provide that information to our community?  If it's not, how do we then build a team?  Who needs to be in my research team?  How do we then get funding together to take this idea forward?”  So, it's really taking the model, taking the good practice that already existed and creating an online platform to really attempt to replicate that as best we can. So the platform will launch on 23rd November (2024) at CamRARE's Rarefest which is a lovely in-person activity that's going on in Cambridge, and that platform will be open to anyone who has an interest in rare disease research.  But I think, critically, what's different about this is that, you know, we've talked about setting research agendas and we've talked about patients contributing to that, contributing to setting the priorities, what's different here is that the patients decide on the questions; it's what matters to the patients coming from them and their community.  And it's an opportunity for them to showcase those questions and those idea on a platform and almost to have a call to action, “Is there anyone else on this platform who has similar research interests to me?”  The platform will matchmake them together through a series of choosing tags, choosing tags about particular disease areas -  It's linked to the Orphanet database - choosing tags about the type of research that you're interested in.  That matchmaking process will happen, which at the moment is a very serendipitous process but we hope to take it a little bit further on from that.  It's still going to be a little bit of potluck who's on the platform at the time who's got similar interests as you but hopefully it will improve that serendipitous system.  And it will allow them to access resources on the platform, which is the kind of hand-holding bit, and also, critically, some mentoring.  So, there's a real sort of opportunity here for professionals – researchers, industry partners, healthcare professionals – who have particular skills in research to be able to say, “Well I can help.  I might not be able to be part of your team at this point but if you need half an hour on a Zoom call with me to think about your research question I can offer to mentor you on that.”  But, likewise, I think there's going to be lovely opportunities here for patient groups to support each other too because what we've always realised is that patient groups are at different points of their research journey.  You know, we see some organisations that are really well-funded now who are in partnership with industry, you know, they have a group of pharma companies that are supporting the development of treatments and they've kind of reached that point where they're very highly skilled and very well experienced.  And then there's others who are mum and dad who've just had a recent diagnosis for their child, they've gone searching on the internet, they can't find information, they don't have a patient organisation to rely on so they're going to make one themselves.  This happens all the time in the rare disease field.  There are 11,000 different rare conditions and there's not a group for all of them so mum and dad will often start something themselves and then in lots of cases want to do some research, they want to answer some of these questions.  So, you know, they're really starting from a very different beginning stage here where they've going to need some help, and sometimes the best help comes from their peers, it comes from other patient groups.  So that's in a nutshell what it's about; it's about providing opportunity for patient groups to showcase their great ideas, build partnerships and take research forward.   Rona: The only thing just to add there is I think, although rare diseases are individually rare, collectively, as Jo said, they're quite common, there's 11,000 rare diseases, and often, although they all have distinct features, there are common threads through rare diseases in terms of maybe symptoms that patients experience or challenges that their rare disease brings.  So, for example, you may have symptoms of pain or seizures that are common across many conditions, there may be educational needs that are threads going through.   And groups could work together maybe to answer a question that's relevant to a number of conditions and so bringing people together for that.  Or there may be another group that's already tried to answer that question in their condition and you can learn what worked, what didn't work.  I think that's the other thing, is there will be common threads that come through, and I think that would be a real strength of the network to draw those people together. Jo: I think as well, Mel, if we take this back to what we said right at the outset about optimising success for patients by bringing them into the conversation early, I think this platform provides the perfect opportunity to do that.  So we're moving away from, we're really turning research on its head, moving away from it being a researcher-led activity where they decide on the idea and the research concept and bring patients in at different points along that research journey and instead starting with the patient's idea in the first place.  It can only be a better system for all because it improves efficiency, it improves potentially the long-term outputs and, most importantly, outcomes for patients.  Mel: We were that family, that mum and dad setting up the charity a year and a half ago for the ultra-rare disease that our children had.  I think, you know, the match-making opportunities that are here are fantastic because finding yourself in that position is incredibly isolating.  And not only the matchmaking opportunities with the researchers but, as you were saying, Rona, as well with similar diseases; there's so much to learn from other diseases that may have, I don't know, a similar phenotype in the cells or similar symptoms.  That's what we found from connecting with these other rare conditions.  So, for us it's lysosomal storage diseases, we've now got the opportunity potentially to piggyback on drugs better used for their diseases for our own ultra rare condition, you know, where for us to run a full-on clinical trial by ourselves with a new drug, I mean, we just wouldn't have,  there's no funding, there's not enough interest.  So, I think the opportunities that lie in this network are really, really exciting.  Jo, can you tell me a bit more about who can join the research network?  Jo: So anyone with a rare disease research interest. That's everybody from individuals affected themselves, their family members, their caregivers, the patient organisations, that support them, and then, you know, all sorts of rare disease professional researchers.  So, we're looking for PhD students who are looking for their first exciting project to undertake, have they taken a look at the Rare Disease Research Network to see if there's any ideas that might pique their interest.  We're looking for established researchers, medical professionals who are undertaking clinical research but also I think, importantly, companies.   You know, we hear more and more about concepts like drug repurposing for rare diseases where we're looking at the opportunities for taking drugs that already exist and have been proven safe to be redeployed to other rare diseases. It's quicker, it's more efficient, it's cheaper, so does it open up opportunities for companies that are using that technique to get involved.  And also pharma companies.  This platform is not all going to be about finding cures and treatments but it certainly will be a priority for some groups.  So we really are welcoming everyone with an interest in rare disease research to get involved, be part of the network, collaborate, help where you can. Rona: And also, as we've said before, once you've got that level of engagement and the patients leading these initiatives we've found, certainly with our group, the patients are much more willing to, say, find the MRI scans for the scientists, to have a blood sample done, to have skin fibroblasts taken.  If they know and they understand and they're driven and, as you said, the research idea has come from them as a patient group it certainly increases the chance of them being fully involved in the project from the start to the finish.  And all these things are imperative to understanding rare conditions because without researchers having the opportunity to look at these various samples you're not going to stand much of a chance of finding a treatment.  Jo: And we want the opportunity to upskill patients as well.  I think there are many people out there with great ideas who haven't yet found the confidence to promote those ideas because they're not quite sure of what the research journey looks like or what it might entail or whether they've got the right skills.  But I think by joining the platform and almost kind of watching how other people are managing these things and utilising the resources and the mentoring I do really hope that will build that confidence and those skills sets in people so that they can engage.  Rona: Yeah, just to add to that, I don't think it's just upskilling patients and patient groups, I think it's upskilling everybody involved in rare disease research.  This is quite a different way of approaching research, it's something that maybe academics may feel a little bit uncomfortable with, it's not how it's normally done, so I think there's a whole learning process.  And the aim is that this RDR network will evolve and will develop and the direction it goes will be driven by the community that are engaging with it.  So I think it's a really exciting time just as we're coming up to launch to see where this goes.  Jo: Mel, you've been involved in this project, it would be really interesting actually to hear from you. I was just thinking, as part of the co-creation community we had 25 individuals from the rare disease community who built this platform from scratch with us; Rona and I might have set out all the vision for how we wanted the platform to be or what we thought might be a good idea but ultimately it was the community who decided and they literally have fact-checked and cross-referenced every word that's gone on the platform. What has that experience been like for you as a patient representative?  Mel: I think it's been really welcome to see a network that is truly putting patients at the centre of everything.  So, from the very beginning foundations you have the rare disease community involved which is exactly what you're trying to create through your network.  So, I think it's been very welcome to be involved in the project and I also think that hopefully it will sort of be self-perpetuating that this will start to press a reset button on how we think about rare conditions and how it needs to be a more equitable field with patients.  Because I think, as you've both alluded to, while some clinicians and researchers are very onboard with this, for others it's a new concept that they still need to potentially adjust to or get their head round because it is a different way of thinking.  But in rare disease, well, in any condition really but particularly rare disease because there's so few experiences to draw on, I think that patients are vital to moving forward and to making that change so that diseases and conditions that have previously had no treatment, like, hopefully this way of thinking can expedite those treatments because, well, as a rare disease representative myself for our community that's one of our biggest drivers.  We're dealing with a condition that's progressive that affects most of our community's children; that is what we want, we want treatment, we want something that can stabilise the conditions.  You know, you can have researchers doing random projects that would make no difference to the final outcome of patients but if researchers know it's a priority of this particular group, hopefully that can channel in their focus and get the outcomes that the patients want in a more timely collaborative way.  So, I am a huge advocate for what you're doing, I think it's an incredible initiative.  Is there anything either of you would like to add to that? Rona: Rare disease disproportionately affects children and young people.  So, 7 out of 10 rare diseases develop in childhood and at the moment the Rare Disease Research Network hasn't really got a forum for including children and young people, and really that's partly because, and Jo can speak much more eloquently to this with her experience.  Actually, we didn't do that at the start because we feel that this is actually a discreet piece of work that really needs to be done in collaboration with children and young people to make sure that it's done well so that they can engage in the platform. So, Jo, I don't know if you want to talk about how we're hoping to take this forward.  Jo: Yeah, so we're busy developing a project plan at the moment which we're hoping to get funding for to work over eighteen months with a team of young adults with rare conditions, probably from our Unique Feet community and keep it local because we already have a good relationship with them and they have our trust.  But the idea would be to work with lots of other young people's forums.  So there's already ones established in and around our area, such as Pedal, which works with really small children, and there's also groups that are set up for young people with cancer.  So we've already had lots of great conversations with them about how we can work with them, how they can help us sense-check our project, and then in return we can help them better understand research and their ability to be involved in that.  But ultimately by the end we want to run focus groups, we want to develop some peer mentors within our community, so young adults who've, you know, perhaps come out the other end of a period of transition into adulthood who can support other young people with rare diseases to also become researchers, to come up with their own ideas and their own questions, and to sense-check projects that come through the platform.  So it's a really exciting opportunity to truly involve the people who are affected most by rare conditions but we know through our My Story, My Way project that this has to be done gently, carefully, given time and done really thoughtfully.  So that's our next step and we hope to be able to share those learnings with people so that it can be done elsewhere.  Mel: And do you see the network also working with children with learning differences? Jo: Absolutely.  We'll invest a lot of time and energy in ensuring that materials are accessible, inclusive and suitable for the community that we're working with.  Mel: So looking to the future, how do you think, Rona, can patient-led research help to shape the future landscape?  Rona: So I think, Jo used the term earlier, kind of this is really turning research on its head, so it's really putting patients right at the centre of research, so it just makes sure that it's absolutely driven by what matters to them to get the outcomes that matter.  And, again, it's just got all that benefit of efficiency and really answering those questions that matter.  Mel: And, Jo, do you think this could lead to more collaborative partnership, for example, between industry and academia, potentially leading to quicker clinical advancement? Jo: I would absolutely like to think so.  You know, as CamRARE we run a companies forum which is a roundtable meeting for pharma and biotech companies and other organisations like Genomics England who are involved in the rare disease therapeutic space and diagnostics, and I think one thing that I find really heart-warming about those meetings is that, you know, different companies are able to sit around a table as competitors but with a very open mind to addressing the barriers and the bottlenecks that prevent them from getting drugs to patients.  Because of course it's not just the research journey that's a challenge, it's the regulatory side of things at the end of that journey; just because you've created a great drug it doesn't matter in the end if it doesn't get to the patient.  So, you know, access is critical and involving patients at the earliest possible moment to ensure that that treatment gets through to the regulators and gets access to patients is the only way forward.  We had a recent companies forum meeting where we were exploring health-related patient reported outcome measures, or PROMs, and we had a speaker from NICE who's the regulatory body, we had a speaker from Sheffield University who was talking as an academic about developing PROMs for industry and for patient groups and we had Emily Reuben, the CEO of Duchenne UK, and we had an amazing discussion about the importance of involving the patient community from the outset.  And the academic explained that developing a PROM for Duchenne UK had taken them two years and it had taken them that length of time because they'd followed this careful thoughtful pathway of making sure that they didn't assume anything about what matters to patients.  But that of course, as we said earlier, involves time, it involves financial commitment, it involves resources and the right attitude, but I do think that a platform like the Rare Disease Research Network can really try to harness all of those things by bringing the right people together – industry, academia and patients – to work together equitably. Mel: And with the network do you think you'll be getting the regulators in at that initial stage as well so that, like you said, the patients can gain access while we're dealing with their priorities, the regulators are informed at the very earliest stages so that we know the process that's being followed will ultimately lead to patients gaining access to the relevant therapies?  Jo: Yes, I think this is really important, and there's actually, we've got a section on the new platform which really talks to each of the different stakeholders.  ‘What's in this for me?'  ‘Why is it important for you to be here and to join?'  And one part of that is funders and that includes the regulatory bodies.  And at the next companies forum meeting we're actually going to be bringing the Rare Disease Research Network Platform and its potential to the companies forum meeting and we'll have regulators involved in that.  So, you know, we are constantly talking to people about why it's important for them all to be involved and all to see what matters. I think I'd like to advocate for an extra letter at the end of PPIEP - if we could squeeze a D in there at the end too.  So over time that terminology has expanded to be Public Patient Involvement Engagement and Participation, which was added I think this year, but it would be lovely to have the D on the end and to include ‘Driven' because I think what's really important about this platform is that it's not just engagement and involvement, it's not just participation, it's initiated by and driven by patients. Mel: So I think we'll wrap here.  Thank you to our guests, Jo Balfour and Dr Rona Smith, for joining me today as we discuss the role of patients in setting research agendas.  If you'd like to hear more like this, please subscribe to Behind the Genes on your favourite podcast app.  Thank you for listening.  I've been your host, Mel Dixon, and this podcast was edited by Bill Griffin at Ventoux Digital and produced by Naimah Callachand. 

Contributor: Alec Coston MD Educational Pearls: Causes of seizures in a fairly well-appearing child with diarrhea: Electrolyte abnormalities: hypocalcemia, hyponatremia Also hyperkalemia which causes arrhythmias and syncope - can appear like seizures Hypoglycemia If the child has diarrhea and appears very sick, differential diagnosis may include: Hemolytic uremic syndrome (HUS): simultaneous occurrence of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury Typically caused by Shiga-like toxin producing Escherichia coli (also known as EHEC, or enterohemorragic E. coli) One of the main causes of acute kidney injury in children Toxic ingestions such as salicylates, lead, or iron In this case, the child had a seizure but appeared well and was afebrile: Consult with neurology led to a diagnosis of benign convulsions with mild gastroenteritis (CwG) First identified in 1982 in Japan Viral gastroenteritis with diarrhea and convulsions but does not include fever, severe dehydration, or electrolyte abnormalities Uncommon illness caused by rotavirus and norovirus pathogens Criteria for discharge is similar to a febrile seizure - the patient had one seizure that lasted less than 15 minutes and he quickly returned to his baseline, so he was able to be safely discharged home This diagnosis does not predispose him to epilepsy later in life References Lee YS, Lee GH, Kwon YS. Update on benign convulsions with mild gastroenteritis. Clin Exp Pediatr. 2022 Oct;65(10):469-475. doi: 10.3345/cep.2021.00997. Epub 2021 Dec 27. PMID: 34961297; PMCID: PMC9561189. Mauritz M, Hirsch LJ, Camfield P, et al. Acute symptomatic seizures: an educational, evidence-based review. Epileptic Disorders. 2200;1(1). doi:https://doi.org/10.1684/epd.2021.1376 ‌Noris, Marina*; Remuzzi, Giuseppe*, †. Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology 16(4):p 1035-1050, April 2005. | DOI: 10.1681/ASN.2004100861    Summarized by Meg Joyce, MS1 | Edited by Meg Joyce & Jorge Chalit, OMS3 Donate: https://emergencymedicalminute.org/donate/  

Host: Darryl S. Chutka, M.D.   Guest: Aleksandra Kukla, M.D. In 2023, an estimated 14% of all adults in the U.S. or just over 35 million individuals had chronic kidney disease and it's even more common in the elderly population affecting over 1/3 of those over the age of 65. It represents the 8th leading cause of death in the U.S. It's now known that chronic kidney disease is associated with systemic inflammation, which is responsible for a variety of complications including atherosclerosis and subsequent cardiovascular disease. Does kidney disease result in inflammation or does inflammation produce renal dysfunction? Are there inflammatory markers we could measure to assess this inflammation? Can we do anything to reduce the inflammation and if so, does it improve patient outcome? These are just some of the questions I'll be asking my guest, Aleksandra Kukla, M.D., from the Division of Nephrology at the Mayo Clinic as we discuss “Chronic Kidney Disease as a Systemic Inflammatory Syndrome”. These talks on Inflammation and Cardiometabolic Disease are sponsored by Novo Nordisk Learn more about this series HERE Connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

CME credits: 0.25 Valid until: 21-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/current-experiences-in-identifying-and-treating-itch-in-patients-on-hemodialysis/26638/ Patients with chronic kidney disease may be experiencing severe itch, known as CKD-associated pruritus (CKD-aP). Itching and related symptoms, such as reduced sleep and depression, may be causing a significant negative impact on their quality of life. Join our experts as they use real-world patient cases to illustrate how to identify and treat itch, provide relief from itch-related symptoms, and improve quality of life in your patients with CKD-aP.=

CME credits: 0.25 Valid until: 21-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-outcomes-in-patients-with-igan-novel-therapies-and-evolving-guidelines/26627/ Given that IgA nephropathy is a leading cause of kidney failure, early diagnosis and treatment are essential. In the landscape of the many evolving treatment guidelines, how can nephrologists apply emerging evidence and utilize newer therapies to achieve proteinuria remission and maintain eGFR to improve the outcomes of their patients? Hear the experts answer these questions by reviewing a real-world clinical patient case.=

Thanks for tuning in for a RERUN episode.   Was the women's ASIFA a success? Why was it so inspiring? Why were so many many turned off? What did they do right? How could have it been better?  How does Charedi leadership feel about women, their roles and right for self expression? Listen to this episode to hear a frank discussion that brings up all sides.  Check out the original episode on this show with Dr. Efrat Bruck: https://podcasts.apple.com/us/podcast/lets-talk-about-the-issues-brought-up-in-my/id1316933734?i=1000529763337     Link to the latest music release "Times Of Our Lives": Kol Isha https://www.youtube.com/watch?v=LypQ6opliv4&feature=youtu.be   If you'd like podcast support, please reach out to franciska@franciskakosman.com   If you'd like to book a consult session with Franciska, click here:  https://checkout.square.site/merchant/5BECR8D49NYV3/checkout/FVSNPB7HVW36LOYAR3L7SJMU   If you'd like to sponsor an episode, click here: https://checkout.square.site/merchant/5BECR8D49NYV3/checkout/6KYMG7OGFR4Y63C43RREZ5MV Check out www.JewishCoffeeHouse.com for more Jewish Podcasts on our network.   ABOUT OUR GUEST: Efrat Bruck, MD, graduated from the Icahn School of Medicine at Mount Sinai in New York City and is now an anesthesiology resident at the Mount Sinai Hospital. Before medical school, she taught Judaic studies, Hebrew, and Biology to 1000 now-alumni of Be'er Hagolah Institutes, in Brooklyn, NY. Dr. Bruck has worked as a content specialist for Khan Academy and created over 30 MCAT preparation videos on topics in molecular biology, DNA, and genetics that have also recently been translated into foreign languages.  Her videos have been published on the AAMC (American Association of Medical Colleges) website, Khan Academy, and YouTube, accruing millions of views on the latter. Dr. Bruck has published research in Nature, the Journal of the American Society of Nephrology, and Obstetrics and Gynecology. Dr. Bruck founded and leads the JOWMA PreMed Society that aims to advance Jewish women, from all backgrounds, in medicine. Dr. Bruck is a fierce advocate for premed students from insular and underrepresented backgrounds and strives to provide them with the resources and tools necessary to compete. (www.jowma.org/pre-med). She was among two out of 200 graduating MDs, PhDs, and MD/PhDs at Sinai's recent commencement to be awarded the Patricia Levinson Award for the Advancement and Inclusion of Women in Medicine. Dr. Bruck, along with her colleagues at JOWMA, is also currently in the process of constructing a cultural competency curriculum that will help healthcare professionals in New York City hospitals provide culturally sensitive medical care to Jewish populations across the entire spectrum of Orthodoxy. Dr. Bruck's experiences in education, acceptance to nearly 10 US MD programs, and service on the admissions committee of the Icahn School of Medicine at Mount Sinai have led her to have a highly successful track record helping premeds navigate the medical school application process. She is the founder and CEO of MDInspire, a medical school admissions consultancy that provides professional consulting for fees that are reasonable and a fraction of the standard costs. Dr. Bruck specializes in helping people weave their stories seamlessly through their application, building stellar personal statements and activities sections, interview preparation, and coaching students on how to study smarter, not harder. For more information, please visit: www.MDInspire.com. BlogPost: http://www.rationalistjudaism.com/2021/07/from-bais-yaakov-to-md.html Instagram: drbruck_mdinspire Facebook: Efrat Bruck LinkedIn: Efrat Bruck, MD website: www.MDInspire.com YouTube: Efrat Bruck www.jowma.org/pre-med

Did you miss AHA 2024? Listen here to brief discussions of the latest research. Eric Rubin is the Editor-in-Chief of the Journal. Jane Leopold is a Deputy Editor of the Journal. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin, J. Leopold, and S. Morrissey. NEJM at AHA — Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. N Engl J Med. DOI: 10.1056/NEJMe2414476.

On this ASN Kidney Translation episode, Dr. Matthew Sparks hosts discussions on nephrology research in genetics. Topics include genetic testing in CKD, ADTKD screening, and digenic Alport syndrome insights.

Dr. Frita Fisher, who is triple board-certified in Nephrology, Internal Medicine, and Pediatrics, engages in a discussion with Lori Hartwell about the role of phosphorus and its impact on overall health. Join them as they explore what phosphorus is, why it is present in many foods, and why people with kidney disease are more likely to experience elevated phosphorus levels. They also cover the symptoms and health risks associated with high phosphorus levels, as well as both traditional and emerging treatment options to help maintain normal phosphorus levels for improved well-being.

Swapnil Hiremath, MD, MPH, FASN, joins Hiddo Heerspink, PhD, and Meg Jardine, MBBS, PhD, to discuss clinical trials presented at Kidney Week 2024, including notable findings from accepted submissions and late-breaking clinical trial sessions.

Swapnil Hiremath, MD, MPH, FASN, joins Hiddo Heerspink, PhD, and Meg Jardine, MBBS, PhD, to discuss clinical trials presented at Kidney Week 2024, including notable findings from accepted submissions and late-breaking clinical trial sessions.

Leading health care professionals Edwina A. Brown, MD, MBChB, Timothy Ray, CNN, CNN-NP, DNP, NP, and Monnie Wasse, MD, MPH, FASN, share their perspectives on evolving advances in dialysis treatments and patient care in the US and across the globe.

Kidney Week 2024 on the go. Gentzon Hall, MD, PhD, FASN, Matthias Kretzler, MD, and Heather Reich, MD, PhD, discuss progress in glomerular disease research, emerging trends, and clinical challenges.

Kidney Week 2024 on the go. Gentzon Hall, MD, PhD, FASN, Matthias Kretzler, MD, and Heather Reich, MD, PhD, discuss progress in glomerular disease research, emerging trends, and clinical challenges.

Episode 178: Social Media in MedicineDr. De Luna and Dr. Song explain the role of social media in medical education and how online journal clubs have become more useful in recent years.  Dr. Arreaza offers insights into our role as educators and sources of truth.Written by Patrick De Luna, MD. Comments by David Zheng Song, MD, and Hector Arreaza, MDYou are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Intro to episode (voiceover): Get ready to listen to a great conversation between three doctors diving into the impact of social media on medicine. It's no secret that social media shapes our lives—not just as professionals, but also as humans and members of our society. Every second, new information floods our feeds, and with the rise of artificial intelligence, it's becoming harder to separate fact from fiction. As doctors, we have a crucial role in clearing up confusion and supporting evidence-based practices. You'll hear insightful tips from Dr. De Luna, Dr. Song, and Dr. Arreaza—but remember, you also have a role in spreading the truth, you must be a reliable source of online truth and correct misinformation quickly. Also, use reliable sources, recommend fact-check websites, including Snopes, and FactCheck.org, and avoid “back-and-forth” arguing about fake news online, because as you keep arguing, fake news will continue to spread.Social Media in Medicine.Patrick: Social media has helped both physicians and patients obtain and expand their knowledge of medicine. This role in medical knowledge expansion has been more prevalent since the COVID-19 pandemic, especially in the form of podcasts (like this one), medical content creators, and personalities.  This growing medium has helped physicians to deliver medical knowledge in an efficient, but layman, format which can become a great outreach and educational tool. Arreaza: This podcast was created 3 days before the lockdown. It has been an educational tool for those who record and hopefully for those who listen to us.Patrick: In today's episode, we will explore a little about how this more accessible approach to medical learning has shaped our medical education landscape. We'll explore a recent study that shows the breakdown of how social media is used among medical professionals and the concerns that physicians have about medical education through social media. We will discuss how platforms such as X/Twitter have “Journal Club” threads and their implications. Furthermore, will discuss how online personalities have been able to bring medical education discussion to the broader population, and what we can learn from their work. David: Who is your favorite medical educator?Patrick: Dr. Mike (YouTube FM), Dr. Glaucomflecken (ophthalmologist comedian), and HealthyGamerGG (gamer), and yours?David: Curbsiders (THE internal medicine podcast)Arreaza: I like Dr. Glaucomflecken as well. He is a comedian but he is becoming a little more political. The AFP podcast is my favorite.David: We will explore and discuss how we could make quality and accurate medical education content and, hopefully, mitigate concerns about creating future educational content for physicians and patients alike. Analysis of Healthcare Professional Social Media UsePatrick: Social media has traditionally been used to share about your social life (posting pictures of your cat and family vacation), stay up to date on news and what is happening among your peers, as well as (for some select folks) a platform for content creation and a means of a career. Healthcare professionals also participate in social media in the same manner. David: Some social media users are called “influencers”. Arreaza: The term “influencer” is becoming a somewhat negative term online because many “influencers” are giving a bad reputation to that term, to the point that many prefer to be called “content creator.”Patrick: In a recent study published in Taylor and Francis' Medical Education Online, 72.1% of the participants reported use of social media to some degree. Out of the 72%, 11.5% of the surveyed report using social media sites exclusively for professional purposes, 22.8% for strictly personal use, and 65.7% for both. David: The most used social media platforms among healthcare workers were Facebook at 70%, YouTube 58%, LinkedIn 52%, Instagram 42%, Twitter (now called X) 27%, TikTok 10%, and Reddit at 5% among those surveyed. Those are 6 different media, which ones do you currently use, Patrick?Patrick: [Add response]. 20.4% of the surveyed indicated they use clinically focused social media platforms as well. This same survey found that respondents specializing in addiction medicine, family medicine, pediatrics, and psychiatry were more likely to use social media for continued professional development as compared to other specialties. David: Social media among the participants was highly used for staying informed with medical news and actively participating in medical discussions online, especially about medical management and treatments. Of note, the data is based on a population that skews more toward physicians and medical professionals who have practiced for more than 15 years. Arreaza: Doximity is one of those platforms that I have used in the past, and it contains interesting articles but they have to be read “with a grain of salt,” because they are editorials.The “New Journal Club” OnlinePatrick: Multiple residency programs report using social media as a form of engagement about published journal articles and updates to medical practice. Medical education may benefit from the implementation of social media and similar platforms as a medium for professional development, according to an analysis performed by Medical Education Online. The use of social media among many physicians has changed from content consumption (passive) to active participation in furthering medical education. David: This is reflected heavily in how platforms such as X (formerly known as Twitter), have become a forum towards a new form of “Journal Club”.Tweet Threads can now be utilized for further publication discussion in an open online space.  Good examples of this can be found among Twitter feeds from publication sites like the New England Journal of Medicine or #IDJClub (Before their move to Meta's Threads in November 2023). The Infectious Disease Journal Club, using the handle @IDJClub, published a study in May 2022 highlighting the impact of 20 months of journal club hosting through Twitter.Patrick: The authors of the study state that it may be harder for physicians outside of academic circles to have opportunities for well-scaffolded discussions and continued maintenance of critical appraisal skills. Due to an explosion of questionable medical literature during to COVID-19 pandemic (AKA fake news), they report a higher need for avenues to keep the practice of critical appraisal, thus we need to expand journal club access outside of academic sites.Arreaza: From May 19, 2019 – August 7, 2021, the @IDJClub account was followed by almost 9,500 followers from 114 countries and hosted 31 journal club posts and discussions. During the study, they found data that shows a decrease in participation in journal clubs use in residencies, as well as a lack of expert hosts to lead those discussions. Patrick: In addition to the increased accessibility, the survey makes a case that online interdisciplinary journal clubs can be an effective tool to update medical professionals and for practicing critical appraisal of the research studies. 75% of respondents believed that they learned more from these #IDJClub discussions than in their traditional journal club forums (if such forums were available to their respective programs). A case is made where it could be reflective of easier access, the make-up of how the publication is presented, and how the overall journal club is run. Concerns and Challenges to AvoidDavid: As well-intended and useful as these platforms for medical education can be, some authors from AAFP recommend that we be mindful of problems that can occur from misapplied use. Patrick: One problem that has been brought to the AAFPs' attention is potential society and licensing board actions. Medical boards, such as our own California Medical Board, can sanction physicians, uphold practice restrictions, or even take away physician licenses due to unprofessional behavior in social media content creation. This is especially worrisome if posting scientifically misleading or untrue claims.David: One example was an incident here in Bakersfield where 2 physicians used YouTube to post the results of COVID-19 tests at their urgent care during the peak of the pandemic. They misled the public in stating the disease did not have serious ramifications as the CDC stated. Due to the large number of viewers, the physicians were censured by medical societies due to their distribution of biased and unfounded information to the public. Patrick: AAFP authors suggest that for medical statements and discussions posted on social media for general patient education, it is recommended to add hyperlinks or direct sources with any online interaction in-so-that it better qualifies accuracy. If it's unverifiable, it would be best to add written caveats about the information's non-verifiability or that it is in the process of continued research. Patrick: At this time, there is some effort made by social media platforms to help indicate that the post is made by a reputable source. For example, when a licensed medical professional posts on YouTube, there are information panels that appear that will give context to the health content that is viewed. At the time of this episode, YouTube also currently allows channels to apply to be indicated as a licensed medical professional in the channel's posts. The applicants are examined by three different medical societies: the Council of Medical Specialty Societies (CMSS), the National Academy of Medicine (NAM), and the World Health Organization (WHO) to standardize how health education should be shared online. David: An example being Dr. Lin of Common Sense Family Doctor, an online medical blog for patients and physician education. In his statement to AAFP, he states that he wanted to post educational content twice a week, however, it required 3 to 4 hours a week to create. This can be time-consuming and distracting from other responsibilities.Arreaza: Social media can change mind. What other concerns do you think should be considered when physicians try to educate patients in an online environment?Social Media Platforms to Teach Medicine to the Greater Public Patrick: In general, social media platforms can be used to educate the public. One AAFP panel of authors wrote that some key points are important to consider when creating online content that is meant for public use.We must define our goals toward the subset population we are directing the education towards. Is it providing general health education? Is it promoting a practice? Is this used to advocate for a cause?We must consider who our audience is. For example, if our goal is to create a professional message to incite political or societal change towards public health policy, it would be best to utilize platforms that involve policymakers, political leaders, and/or patients that can inform them of what we want to achieve. Focus on general topics. These can include topics such as viral medical discussion trends on platforms like TikTok (ex. Ozempic), fitness and wellness, nutrition, or topics that you yourself have interest or expertise in. This can lead to the production of original content such as informatic YouTube series', podcasts such as this one, or discussion threads. AAFP recognizes that this can become a creative outlet for physicians and can reduce burnout.ConclusionPatrick: We can see the transformative impact of social media on medical education, and how it's further evolved since the COVID-19 pandemic. We explored how platforms like Twitter have redefined traditional journal clubs, making scholarly discussions more accessible across global medical communities. Moreover, we examined the role of influential medical content creators in bridging the gap between healthcare professionals and the general public. Patrick: While social media presents unprecedented opportunities for disseminating medical knowledge, our discussion also highlighted the challenges, including the need for accuracy in content, navigating professional conduct, and addressing algorithmic biases that can influence online interactions.Patrick As we conclude, it's evident that social media has revolutionized medical education by fostering broader engagement and democratizing access to knowledge. However, both physicians and content creators must uphold ethical standards and ensure the accuracy of information shared online. By navigating these challenges thoughtfully, we can harness its full potential as a powerful tool for advancing medical education and improving health outcomes in our local communities. ____________________This week we thank Hector Arreaza, Patrick De Luna, and David Zeng Song. Audio editing by Adrianne Silva. Intro by Raj Ajudia, MSIII. Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________Links:Topf, Joel M., Introduction: Social Media and Medical Education Come of Age, Seminars in Nephrology, Volume 40, Issue 3, 247 – 248. https://www.seminarsinnephrology.org/article/S0270-9295(20)30043-7/fulltextNguyen BM, Lu E, Bhuyan N, Lin K, Sevilla M. Social Media for Doctors: Taking Professional and Patient Engagement to the Next Level. Fam Pract Manag. 2020;27(1):19-14. https://www.aafp.org/pubs/fpm/issues/2020/0100/p19.htmlIserson KV, Derse AR, Delpier M. Navigating the Hazards of Social Media. Fam Pract Manag. 2022;29(3):15-20. https://www.aafp.org/pubs/fpm/issues/2022/0500/p15.htmlVan Ravenswaay L, Parnes A, Nisly SA. Clicks for credit: an analysis of healthcare professionals' social media use and potential for continuing professional development activities. Med Educ Online. 2024 Dec 31;29(1):2316489. doi: 10.1080/10872981.2024.2316489. Epub 2024 Feb 15. PMID: 38359156; PMCID: PMC10877644. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10877644/Doctor Mike, YouTube Channel, https://www.youtube.com/@DoctorMikeDr. Glaucomflecken, YouTube Channel, https://www.youtube.com/@DGlaucomfleckenHealthyGamerGG, YouTube Channel, https://www.youtube.com/@HealthyGamerGGGet info on health-related content, Google Support, https://support.google.com/youtube/answer/9795167Apply to be a source in YouTube health features, YouTube Help, https://support.google.com/youtube/answer/12796915Theme Song: Works All The Time by Dominik Schwarzer, License #5924333, PremiumBeat.com.  

Learn how to manage diabetes and hypertension in chronic kidney disease with expert tips from Kidney Boy, Kashlak's Chief of Nephrology, Dr. Joef Topf @kidney_boy.  Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Credits Written and Produced by: Fatima Syed, MD, MSc Infographic and Cover Art: Zoya Surani, MD  Show Notes: Fatima Syed, MD, MSc Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP Reviewer: Sai S Achi, MD, MBA, FACP Showrunners: Matthew Watto MD, FACP and Paul Williams MD, FACP Technical Production: Pod Paste Guest: Joel Topf, MD Sponsor: Mint Mobile To get this new customer offer and your new 3-month premium wireless plan for just 15 bucks a month, go to mintmobile.com/CURB.  Sponsor: ClinicalKey AI ClinicalKey AI is an award-winning solution that combines trusted, evidence-based clinical content with conversational search powered by generative AI. To unlock the power of AI in clinical decision-making with ClinicalKey AI, visit Elsevier.health/AI” Sponsor: Freed You can try Freed for free right now by going to freed.ai. And listeners of Curbsiders can use code CURB50 for $50 off their first month.

What if we could redefine what it means to be healthy by setting new medical standards? What if medicine could go beyond treating symptoms and treat root causes?In this episode, the brilliant Dr. Shai Efrati enlightens us on a revolutionary concept, enhanced medicine, which goes beyond conventional treatments and focuses on the body's natural healing abilities. Dr. Shai Efrati is a renowned Physician and Professor at Tel Aviv University, specializing in Internal Medicine, Nephrology, Clinical Pharmacology, and Hypertension. He is also a pioneer in hyperbaric medicine and the Author of "Beyond Normal: How the New Science of Enhanced Medicine Elevates Peak Performance and Repairs Brain Injuries."Throughout this episode, you'll learn what enhanced medicine is, why it is so revolutionary, and how it can change how we see medical attention, treatments, and self-care. You'll also hear Dr. Efrati's thoughts on the importance of focusing on root causes, personalized approaches to improve patient care, the multiple benefits of hyperbaric chambers, and much more.Tune in to episode 445 of Becoming Your Best and discover why enhanced medicine can change how we think about health and wellness.Some Questions I Ask:Tell us about your book "Beyond Normal" and why you wrote it (2:10)Let's take someone who has been having headaches for a year and hasn't figured out why. Using your approach, what would you do with that individual? (9:50)In This Episode, You Will Learn:Dr. Efrati explains the hyperoxic-hypoxic paradox and hyperbaric chambers (6:40)Why understanding the core biology of symptoms and interdisciplinary approaches is crucial (15:00)Dr. Eftati's golden definition of what it means aging (27:40)Connect with Dr. Shai Efrati:WebsiteLinkedInYouTubeBook: Dr. Shai Efrati - Beyond Normal: How the New Science of Enhanced Medicine Elevates Peak Performance and Repairs Brain InjuriesBecoming Your Best Resources:Becoming Your Best WebsiteBecoming Your Best University WebsiteBecoming Your Best LibraryEmail: support@becomingyourbest.comBook: Becoming Your Best: The 12 Principles of Highly Successful LeadersBook: Conquer Anxiety: How to Overcome Anxiety and Optimize Your PerformanceFacebook Group – Conquer Anxiety Hosted on Acast. See acast.com/privacy for more information.

UTIs - who hasn't had one! Or... thinks they've had? We're talking all things UTIs, pyelonephritis, and all things that ...aren't quite UTIs. Chug some ural, fill your drink bottles, and get some good quality loo roll! Ps Scomo was not on our 2024 bingo card but here we are! Tune in and drink up!

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore the pathophysiology and novel therapeutic strategies to target residual inflammatory risk associated with ASCVD and CKD.    Episode outline:   Moving beyond lipid lowering to address residual inflammatory riskNovel anti-inflammatory targets for ASCVD To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   CME-certified text module with animated pathophysiology video and faculty voice audio clipsClinicalThought commentariesPodcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD 

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore new and emerging strategies to target residual risk associated with systemic inflammation in patients with ASCVD and CKD.    Episode outline:   The relationship among systemic inflammation, ASCVD, and CKD The role of cardiologists and nephrologists in screening and mitigating systemic inflammation To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   CME-certified text module with animated pathophysiology video and faculty voice audio clips ClinicalThought commentaries Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD 

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.    Episode outline:   Colchicine: inhibition of NLRP3 inflammasome assembly/activationCanakinumab (anti–IL-1β monoclonal antibody)Ziltivekimab (anti–IL-6 monoclonal antibody)Other emerging targets/therapies To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   CME-certified text module with animated pathophysiology video and faculty voice audio clips ClinicalThought commentaries Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD 

AKI Tips and Tricks from Joel Topf MD, Kashlak's Chief of Nephrology Get a grip on acute kidney injury (AKI) with Dr. Joel Topf (AKA @kidney_boy), Kashlak's Chief of Nephrology! We've put together an AKI highlight reel - focusing on practical tips and tricks to help you identify, diagnose and manage AKI, plus how to recognize AIN and random myths and musings on vancomycin, NSAIDS, contrast nephropathy, and the risk of NSF from gadolinium. Listeners can claim Free CE credit through VCU Health at http://curbsiders.vcuhealth.org/ (CME goes live at 0900 ET on the episode's release date).  Show Notes | Subscribe | Spotify | Swag! | Top Picks | Mailing List | thecurbsiders@gmail.com | Free CME! Credits Written (including CME questions) and Produced by: Cyrus Askin, MD Infographic by: Cyrus Askin, MD Cover Art: Kate Grant MBChb, MRCGP Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Editor: Matthew Watto MD, FACP (written materials); Clair Morgan of nodderly.com Guest: Joel Topf, MD Time Stamps 00:00 Sponsors - VCU Health CE and Pediatrics On Call podcast by APP 00:30 Intro, disclaimer, guest bio 03:00 Guest one-liner, Picks of the Week*: Zoe Keating albums (Cellist); Mrs. America (TV series) on FX; The Last of Us (Videogame); 08:45 Sponsor - Pediatrics On Call podcast by APP 09:15 Definition of acute kidney injury (AKI) and fundamentals 11:00 Cardiorenal syndrome 12:24 Schema for AKI 17:30 Establish an etiology, determine urine output and address electrolyte abnormalities 21:22 AKI in the otherwise-healthy patient; 32:20 Rhabdomyolysis
38:21 Vancomycin 41:43 Acute interstitial nephritis (AIN) 44:52 Contrast induced nephropathy (CIN) 50:37 Gadolinium in AKI and/or CKD 52:53 Timing of dialysis 
 56:37 AKI in the out-patient setting and how to handle home meds e.g. TMP-SMX, RAAS inhibitors; 62:01 Is Ultrasound necessary in AKI
 64:58 Dr. Topf's take home points and Plug for Seminars in Nephrology 68:45 Outro and Sponsor - VCU Health CE Sponsor: Freed You can try Freed for free right now by going to freed.ai. And listeners of Curbsiders can use code CURB50 for $50 off their first month. Sponsor: Panacea Financial If you're ready to join the thousands of doctors who have declared independence from traditional banks, visit panaceafinancial.com today. Sponsor: Locumstory Tune in to The Locumstory Podcast on Spotify, Apple, or Google podcasts.

Dr. Sayed Tabatabai joins the Glaucomfleckens to talk about his experiences as a nephrologist, from navigating the complexities of the field to recounting a harrowing night in the ICU during a blizzard. — Want to Learn About Dr. Sayed Tabatabai: Socials: Twitter/X : @therealdoctort Instagram: @sayed_tabatabai BlueSky: @therealdoctort.bsky.social Facebook: Sayed Tabatabai — To Get Tickets to Wife & Death: You can visit Glaucomflecken.com/live  We want to hear YOUR stories (and medical puns)! Shoot us an email and say hi! knockknockhi@human-content.com Can't get enough of us? Shucks. You can support the show on Patreon for early episode access, exclusive bonus shows, livestream hangouts, and much more! – http://www.patreon.com/glaucomflecken  -- A friendly reminder from the G's and Tarsus: If you want to learn more about Demodex Blepharitis, making an appointment with your eye doctor for an eyelid exam can help you know for sure. Visit http://www.EyelidCheck.com for more information.  Today's episode is brought to you by the Nuance Dragon Ambient Experience (DAX). It's like having a virtual Jonathan in your pocket. If you would like to learn more about DAX Copilot check out http://nuance.com/discoverDAX and ask your provider for the DAX Copilot experience. Produced by Human Content Learn more about your ad choices. Visit megaphone.fm/adchoices